China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a single-center, randomized, double-blind, placebo-controlled, dosage escalation Phase Ia study. The study will assess the safety, tolerability, and pharmacokinetics of G201-Na in healthy adult males in China.
G201-Na: A Small Molecule GnRH Receptor Antagonist for Prostate Cancer
G201-Na is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that plays a crucial role in the treatment of prostate cancer, which is dependent on androgen in the body. In male patients, G201-Na inhibits the signal transduction of the hypothalamus-pituitary-gonad axis, leading to a reduction in the production and release of endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This reduction in turn lowers the levels of estrogen or androgen, making G201-Na a potential treatment for hormone-dependent diseases such as prostate cancer.
Pre-Clinical Study Results and Clinical Development Prospects
A pre-clinical study has demonstrated that G201-Na has clear efficacy, good safety, and high clinical development value. These promising results have paved the way for the advancement of G201-Na into clinical trials, which will provide further insights into its potential as a treatment for prostate cancer and other hormone-dependent diseases.-Fineline Info & Tech
